Answers are grounded in this paper and cite their sources.
Case report shows novel biomarkers in tumor progression for a rare neuroendocrine tumor, highlighting therapeutic options.
BACKGROUND/AIM: -methylguanine-DNA methyl transferase are important in diagnosis and treatment of NETs. CASE REPORT: We report a rare case of multifocal primary hepatic neuroendocrine tumor (WHO grade 2) in a 79-year-old male. Due to tumor progression under octreotide therapy and the risk of rupture, a multimodal therapeutic approach was implemented. This included initial transcatheter arterial chemoembolization, followed by left lateral hepatectomy and wedge resection combined with intraoperative radiofrequency ablation. Surgical specimens were analyzed for CDK5 and p35 expression. The patient recovered well without complications and was discharged on postoperative day 9. CONCLUSION: In this case, cyclin-dependent kinase 5 (CDK5) and its activator, p35, were identified as potential novel biomarkers in NET. The differential expression of CDK5 and p35 observed in tumors of varying sizes suggests a correlation with tumor progression. These findings highlight the potential of the CDK5/p35 pathway as a therapeutic target for the management of advanced or metastatic NET.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: